ArQule Inc.'s stock plummeted 18.5 percent Wednesday when its partner Kyowa Hakko Kirin Co. Ltd., of Tokyo, suspended patient enrollment in its ongoing Phase III ATTENTION trial of tivantinib in non-small-cell lung cancer. Read More
Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane. Read More
The SEC voted 4-1 Wednesday to approve a proposed rule that pretty much echoes the congressional mandate in the Jumpstart Our Business Startups (JOBS) Act to end the ban on general solicitation and advertising under Rule 506 of Regulation D. Read More
Going against the grain, Ceptaris Therapeutics Inc. is seeking to parlay a single asset in a rare form of cancer into both clinical and financial success. Read More
• Coronado Biosciences Inc., of Burlington, Mass., closed a $15 million secured loan facility with Hercules Technology Growth Capital Inc. Proceeds will support Coronado's clinical programs for Trichuris suis ova (CNDO-201), a biologic therapy for autoimmune disease, and CNDO-109, a biologic therapy for acute myeloid leukemia and solid tumors. Read More
• Noven Pharmaceuticals Inc., of Miami, a subsidiary of Hisamitsu Pharmaceutical Co. Inc., said it submitted a new drug application seeking to market low-dose mesylate salt of paroxetine for the treatment of vasomotor symptoms associated with menopause. Read More
• Collegium Pharmaceutical Inc., of Cumberland, R.I., said it started enrollment in a Phase III study of Oxycodone DETERx (COL-003), a tamper-resistant, extended-release version of oxycodone. Read More
• Hospira Inc., of Lake Forest, Ill., said it entered a deal to acquire an active pharmaceutical ingredient (API) manufacturing facility, together with an associated R&D facility, from Orchid Chemicals & Pharmaceuticals Ltd., in India, for about $200 million. Read More
• Eli Lilly and Co., of Indianapolis, said it is stopping ongoing trials testing promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia, after a recently conducted independent futility analysis concluded that the second of two pivotal studies was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. Read More
